Trial Profile

A Proof-of-Concept, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 in Major Depressive Disorder

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 02 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Nov 2024 According to a Xenon Pharmaceuticals media release, presented Phase 2 X-NOVA data at the Psych Congress, which took place from October 29- November 2.
08 Aug 2024 According to a Xenon Pharmaceuticals media release, company anticipates the first of three planned Phase 3 clinical trials is expected to initiate in the second half of 2024
28 May 2024 According to a Xenon Pharmaceuticals media release, data from this study presented at the American Society of Clinical Psychopharmacology (ASCP) 2024 Annual Meeting in Miami, FL.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com